Literature DB >> 25797993

Roles of oxidative stress and the mineralocorticoid receptor in cardiac pathology in a rat model of metabolic syndrome.

Keiji Takahashi1, Tamayo Murase1, Miwa Takatsu1, Natsumi Matsuura1, Kai Nagasawa1, Takuya Hattori1, Shogo Watanabe1, Toyoaki Murohara1, Kohzo Nagata1.   

Abstract

Oxidative stress and the mineralocorticoid receptor (MR) are implicated in the pathogenesis of salt-induced left ventricular (LV) diastolic dysfunction associated with metabolic syndrome (MetS). We recently characterized DahlS.Z-Lepr(fa) /Lepr(fa) (DS/obese) rats, derived from a cross between Dahl salt-sensitive and Zucker rats, as a new animal model of MetS. We investigated the pathophysiological roles of increased oxidative stress and MR activation in cardiac injury with this model. DS/obese rats were treated with the antioxidant tempol (1 mmol/L in drinking water) or the selective MR antagonist eplerenone (15 mg/kg per day, per os) for 5 weeks beginning at 10 weeks of age. The increased systolic blood pressure and LV hypertrophy that develop in untreated DS/obese rats were substantially ameliorated by eplerenone but not by tempol. Eplerenone also attenuated LV fibrosis and diastolic dysfunction more effectively than did tempol in DS/obese rats, whereas cardiac oxidative stress and inflammation were reduced similarly by both drugs. Both the ratio of plasma aldosterone concentration to plasma renin activity and cardiac expression of the MR and serum/glucocorticoid-regulated kinase 1 genes were decreased to a greater extent by eplerenone than by tempol. Our results indicate that both increased oxidative stress and MR activation in the heart may contribute to the development of LV remodeling and diastolic dysfunction in DS/obese rats. The superior cardioprotective action of eplerenone is likely attributable to its greater antihypertensive effect, which is likely related to its greater inhibition of aldosterone-MR activity in the cardiovascular system.

Entities:  

Keywords:  cardiac remodeling; metabolic syndrome; mineralocorticoid receptor; oxidative stress; renin-angiotensin-aldosterone system

Year:  2015        PMID: 25797993      PMCID: PMC4361530     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  54 in total

1.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.

Authors:  J L Arriza; C Weinberger; G Cerelli; T M Glaser; B L Handelin; D E Housman; R M Evans
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

2.  Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.

Authors:  Tomohito Ohtani; Miho Ohta; Kazuhiro Yamamoto; Toshiaki Mano; Yasushi Sakata; Mayu Nishio; Yasuharu Takeda; Junichi Yoshida; Takeshi Miwa; Mitsuhiro Okamoto; Tohru Masuyama; Yasuki Nonaka; Masatsugu Hori
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-10-05       Impact factor: 3.619

3.  Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome.

Authors:  Christian K Roberts; R James Barnard; Ram K Sindhu; Michael Jurczak; Ashkan Ehdaie; Nosratola D Vaziri
Journal:  Metabolism       Date:  2006-07       Impact factor: 8.694

4.  Outcome of heart failure with preserved ejection fraction in a population-based study.

Authors:  R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9.

Authors:  Kenichi Yokota; Hirotaka Shibata; Isao Kurihara; Sakiko Kobayashi; Noriko Suda; Ayano Murai-Takeda; Ikuo Saito; Hirochika Kitagawa; Shigeaki Kato; Takao Saruta; Hiroshi Itoh
Journal:  J Biol Chem       Date:  2006-11-14       Impact factor: 5.157

7.  Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts.

Authors:  D A Siwik; P J Pagano; W S Colucci
Journal:  Am J Physiol Cell Physiol       Date:  2001-01       Impact factor: 4.249

8.  Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome.

Authors:  Miwa Takatsu; Chieko Nakashima; Keiji Takahashi; Tamayo Murase; Takuya Hattori; Hiromi Ito; Toyoaki Murohara; Kohzo Nagata
Journal:  Hypertension       Date:  2013-09-16       Impact factor: 10.190

9.  Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor.

Authors:  Yasushi Sakata; Kazuhiro Yamamoto; Toshiaki Mano; Nagahiro Nishikawa; Junichi Yoshida; Masatsugu Hori; Takeshi Miwa; Tohru Masuyama
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

10.  Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats.

Authors:  Takashi Yamada; Kohzo Nagata; Xian Wu Cheng; Koji Obata; Masako Saka; Masaaki Miyachi; Keiko Naruse; Takao Nishizawa; Akiko Noda; Hideo Izawa; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  Eur J Pharmacol       Date:  2009-06-06       Impact factor: 4.432

View more
  4 in total

1.  Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome.

Authors:  Yuuri Takeshita; Shogo Watanabe; Takuya Hattori; Kai Nagasawa; Natsumi Matsuura; Keiji Takahashi; Toyoaki Murohara; Kohzo Nagata
Journal:  Hypertens Res       Date:  2015-07-09       Impact factor: 3.872

2.  Aldosterone Disrupts the Intercellular Flow of Glucose in Cardiac Muscle.

Authors:  Walmor C De Mello
Journal:  Front Endocrinol (Lausanne)       Date:  2015-12-11       Impact factor: 5.555

Review 3.  Left Ventricular Hypertrophy: Roles of Mitochondria CYP1B1 and Melatonergic Pathways in Co-Ordinating Wider Pathophysiology.

Authors:  George Anderson; Gianluigi Mazzoccoli
Journal:  Int J Mol Sci       Date:  2019-08-20       Impact factor: 5.923

4.  Glucocorticoid-induced leucine zipper (GILZ) is involved in glucocorticoid-induced and mineralocorticoid-induced leptin production by osteoarthritis synovial fibroblasts.

Authors:  Olivier Malaise; Biserka Relic; Edith Charlier; Mustapha Zeddou; Sophie Neuville; Céline Deroyer; Philippe Gillet; Edouard Louis; Michel G Malaise; Dominique de Seny
Journal:  Arthritis Res Ther       Date:  2016-10-04       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.